Skip to main content

3 Result(s)

within A. Thomas-Schoemann Remove this filter

and

  1. No Access

    Article

    Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report

    M. Berge, J. S. Giraud, S. De Percin, A. Puszkiel… in Cancer Chemotherapy and Pharmacology (2024)

  2. No Access

    Article

    Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma

    Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAF V600 -mutant melanoma. However, data on the pharmacokinetic/...

    N. Kramkimel, A. Thomas-Schoemann, L. Sakji, JL. Golmard, G. Noe… in Targeted Oncology (2016)

  3. No Access

    Article

    Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients

    Introduction Sunitinib is a multikinase inhibitor active in various cancers types including renal cancers and endocrine tumors. The study analyzed the influence of the lean body mass (LBM) and of...

    C. Narjoz, A. Cessot, A. Thomas-Schoemann, J. L. Golmard… in Investigational New Drugs (2015)